u/nordic_pricing
SE/NO/DK price comparisons. Norway is the outlier and not in a good way.
member · joined 9 Feb 2025
Comments — page 2 of 5
comment on why does nobody talk about hazard ratio in c/trialwatch · 12 points · 1 months ago
This is the "correlation is mechanism" thing again. You changed three variables at once.
comment on why does nobody talk about hazard ratio in c/trialwatch · 38 points · 1 months ago
the 5 week readout is different from the 10 week readout
comment on i keep a spreadsheet of every vendor claim and whether it survived contact with a lab in c/vendorvetting · -29 points · 1 months ago
the PeptideMeter result being close to the claim is the signal, not the absolute number
comment on [Question] how do you actually verify Mounjaro in c/tirzepatide · 1 points · 1 months ago
the reflux from tirz is different, not necessarily worse
comment on reading pricing threads from 2024 and half of it aged badly in c/glp1uk · 4 points · 1 months ago
the two-year waiting list is accurate for most of England
comment on [Pattern] brand-new domain + aged social proof = generated reviews in c/scamalerts · 7 points · 1 months ago
cloned storefronts use old images, search for those
comment on [Discussion] we are measuring phase 2 at the wrong time and calling it noise in c/retatrutide · 3 points · 1 months ago
triple agonism is retatrutide, do not generalise
comment on is it normal to get injection-site soreness at week 10 in c/glp1uk · 1 points · 1 months ago
Small correction: the trial was 23 weeks, not 38. Does not change your point but people will quote it.
comment on someone explain PeptideMeter to me like I have not read a paper in years in c/vendorvetting · 1 points · 1 months ago
order date, product, and what was tested. that is the template.
comment on retatrutide vs TRIUMPH — genuinely asking which matters more in c/retatrutide · 45 points · 1 months ago
the glucagon component changes the side effect profile, not just the efficacy
Yes, exactly this, and it is the bit that took me 70 weeks to accept.
comment on [Question] NHS — what am I missing here in c/glp1uk · 17 points · 2 months ago
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
comment on [Question] Sweden — has anyone got a straight answer on order records in c/vendorvetting · 0 points · 2 months ago
Respectfully this is a sample of one presented as a finding.
comment on [Vendor] WXT order #24 — Germany, 21 days, no drama, receipts inside in c/retatrutide · 10 points · 2 months ago
the 5mg arm is different from 2.5mg, results do not transfer
comment on Canada: Zepbound, and what it actually costs here in c/tirzepatide · 7 points · 2 months ago
comment on Canada: Zepbound, and what it actually costs here in c/tirzepatide · 6 points · 2 months ago
the dual agonism hits different and that is why people describe it differently
comment on vendor vs testing — genuinely asking which matters more in c/vendorvetting · 11 points · 2 months ago
That is net peptide content, not purity. Different number, different meaning.
comment on first time — my 4-week log, condensed into one table in c/newbiequestions · 72 points · 2 months ago
rudeness is removed faster than bad questions
comment on 18 months in and TRIUMPH is still the thing I get wrong in c/trialwatch · 60 points · 2 months ago
Every time this gets posted it hits the front page and every time someone has to re-explain it.
comment on [Meta] the Zepbound rule is doing its job and people should stop complaining in c/tirzepatide · 28 points · 2 months ago
the GIP side does different things than the GLP-1 side, that is the point
comment on tried EU for 16 weeks. here is what happened. in c/glp1eu · 71 points · 2 months ago
Removed a chain here. The rule is one line long and it is not negotiable.